Ulcerative colitis Trials in Saint-Étienne, France
Conditions / Ulcerative colitis / Saint-Étienne, France
Research into Ulcerative colitis spans multiple therapeutic approaches and trial phases.
30 total trials for this combination
Showing top 10 of 30 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | RECRUITING | — |
| NCT02100696 | A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors | COMPLETED | PHASE3 |
| NCT06029972 | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | RECRUITING | PHASE2 |
| NCT02925338 | National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life | COMPLETED | — |
| NCT06254950 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | RECRUITING | PHASE2 |
| NCT02536404 | Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE2 |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | TERMINATED | PHASE3 |
| NCT02118584 | Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies | TERMINATED | PHASE3 |
| NCT05598684 | SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases | UNKNOWN | — |
| NCT02447302 | Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis | COMPLETED | PHASE2 |